Quintiles

Browse Information Library
Clinical
Commercial
Consulting
Capital

Therapeutic Areas	Business Needs	Perspectives	Services	Locations
Cardiovascular Central Nervous System (CNS) Diabetes/Endocrinology Infectious Diseases Internal Medicine Oncology Pediatrics Women's Health	Business transformation Clinical and marketing materials Connect with investigators, regulators and physicians Cost control/reduction Enrollment & retention Faster product development Flexible outsourcing Get to market faster High-quality studies Lower portfolio & investment risks Market analysis Targeted communications	Accelerating Outcomes Demonstrating Value Increasing Productivity Medical & Scientific Publications Reducing Complexity Safety & Ethics The New Health	Biostatistics Central Laboratories Clinic Profiles Clinical and Nurse Educators Clinical Monitoring Clinical Pharmacology Data Management ECG For Emerging Biopharma For Medical Devices Government & Non-Profit Late Phase Studies Lifecycle Safety Locations Worldwide Managed Partnerships Market Access Market Access Implementation Market Intelligence	Medical Communications Medical Writing Medical Writing Services Multiple Communications Channels Our Expertise Outsourcing Patient & Investigator Recruitment Patient-Centric Solutions Pharmacovigilance Strategy & Optimization Phase I/IIa Phase II/III Phase IIIb/IV Product and Brand Solutions Product Development & Commercialization Regulatory Regulatory & Quality Sales Models Sales Team Solutions	Africa Asia Australia and New Zealand Europe North and Central America South America

Locations
News
Events
Login

Home >
Browse Information Library >
Videos >
The New Health: James Featherstone on Proving Value

The New Health: James Featherstone on Proving Value

James Featherstone, European Head of Consulting, Bracknell, UK, discusses how the convergence of the clinical and commercial functions within a biopharmaceutical organization will ultimately lead to a better demonstration of a new product's value.

Length: 1:16

Play the video

White Paper

New Voices, New Opportunities: Toward a Patient-Centric Biopharmaceutical Commercialization Model

Biopharmaceutical companies must learn to navigate the increasingly tricky waters of commercializing products by adjusting to the needs of a new set of stakeholders.

Information Library
New Voices, New Opportunities: Toward a Patient-Centric Biopharmaceutical Commercialization Model

Quintiles

The New Health: James Featherstone on Proving Value

White Paper

New Voices, New Opportunities: Toward a Patient-Centric Biopharmaceutical Commercialization Model

Others also viewed